Abbott was recently recognized as one of the world's most innovative companies, securing a spot on the Thomson Reuters 2015 Top 100 Global Innovators list for the third consecutive year.
This prestigious list, established in 2011, recognizes companies around the world for their outstanding commitment to innovation, the protection of ideas and the commercialization of inventions.
New for 2015 was a closer look at the San Francisco Bay Area, where Abbott’s vascular and diabetes care businesses were recognized as top innovators.
Recent examples of Abbott innovation:
The Top 100 Global Innovators list, an initiative of the IP Solutions business of Thomson Reuters, honors the 100 corporations and institutions around the world that are at the heart of innovation, as measured by a series of proprietary patent-related metrics. The full report and related methodology is available at http://www.top100innovators.com.
1. The TECNIS Symfony IOL is not approved or available for sale in the United States. *CAUTION - Investigational Device. Limited by Federal (or United States) law to investigational use.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.